iX Biopharma Ltd. 42C.SI Stock

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. Its lead product candidate is Wafermine, a sublingual ketamine oral wafer for the treatment of acute moderate to severe pain, as well as for depression. The company also offers Xativa, a sublingual cannabidiol wafer for the treatment of anxiety, chronic pain, neuropathic pain, cancer pain, and insomnia; BnoX, a sublingual buprenorphine wafer for the management of moderate to severe pain; and Wafesil and Silcap for the treatment of male erectile dysfunction. In addition, it offers LumeniX, a sublingual glutathione wafer for skin brightening and immunity; WafeRest for the alleviating jetlag and promotion of sleep; and SL-NAD+ supplements product. Further, the company develops Dexmedetomidine for agitation in dementia patients; Dronabinol for chemotherapy induced nausea, vomiting, and anorexia associated with weight loss in patients with HIV/AIDS.; Apomorphine to treat the motor symptoms of Parkinson's Disease; and IXB-321, a vaccine delivery platform. Additionally, it promotes and markets nutritional and supplements products through pharmacies and health food shops, JD and Tmall e-commerce platforms in China, as well as through online store; develops and commercializes of nutraceutical products; and provides laboratory services. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.